CryoPort (CYRX) Competitors $14.00 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$13.96 -0.04 (-0.31%) As of 05/22/2026 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CYRX vs. GPCR, IDYA, ELVN, IRON, and ARQTShould you buy CryoPort stock or one of its competitors? MarketBeat compares CryoPort with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CryoPort include Structure Therapeutics (GPCR), IDEAYA Biosciences (IDYA), Enliven Therapeutics (ELVN), Disc Medicine (IRON), and Arcutis Biotherapeutics (ARQT). These companies are all part of the "pharmaceutical products" industry. CYRX vs. GPCRCYRX vs. IDYACYRX vs. ELVNCYRX vs. IRONCYRX vs. ARQTHow does CryoPort compare to Structure Therapeutics?CryoPort (NASDAQ:CYRX) and Structure Therapeutics (NASDAQ:GPCR) are both pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations. Do institutionals & insiders hold more shares of CYRX or GPCR? 92.9% of CryoPort shares are owned by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are owned by institutional investors. 10.0% of CryoPort shares are owned by insiders. Comparatively, 5.6% of Structure Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is CYRX or GPCR more profitable? CryoPort has a net margin of 41.57% compared to Structure Therapeutics' net margin of 0.00%. CryoPort's return on equity of -7.92% beat Structure Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CryoPort41.57% -7.92% -4.79% Structure Therapeutics N/A -24.91%-23.67% Do analysts recommend CYRX or GPCR? CryoPort currently has a consensus price target of $14.69, suggesting a potential upside of 4.91%. Structure Therapeutics has a consensus price target of $109.25, suggesting a potential upside of 178.77%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Structure Therapeutics is more favorable than CryoPort.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CryoPort 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89Structure Therapeutics 2 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 3 Strong Buy rating(s) 2.89 Does the media refer more to CYRX or GPCR? In the previous week, CryoPort had 2 more articles in the media than Structure Therapeutics. MarketBeat recorded 4 mentions for CryoPort and 2 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 0.68 beat CryoPort's score of 0.12 indicating that Structure Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Structure Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, CYRX or GPCR? CryoPort has a beta of 1.75, suggesting that its stock price is 75% more volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.31, suggesting that its stock price is 231% less volatile than the broader market. Which has stronger earnings & valuation, CYRX or GPCR? CryoPort has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCryoPort$176.18M4.00$78.30M$1.3510.37Structure TherapeuticsN/AN/A-$141.20M-$0.87N/A SummaryCryoPort beats Structure Therapeutics on 11 of the 16 factors compared between the two stocks.How does CryoPort compare to IDEAYA Biosciences?IDEAYA Biosciences (NASDAQ:IDYA) and CryoPort (NASDAQ:CYRX) are both pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment. Which has better valuation & earnings, IDYA or CYRX? CryoPort has lower revenue, but higher earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIDEAYA Biosciences$218.71M11.69-$113.70M-$1.60N/ACryoPort$176.18M4.00$78.30M$1.3510.37 Which has more volatility and risk, IDYA or CYRX? IDEAYA Biosciences has a beta of -0.04, indicating that its stock price is 104% less volatile than the broader market. Comparatively, CryoPort has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market. Do insiders and institutionals hold more shares of IDYA or CYRX? 98.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 92.9% of CryoPort shares are held by institutional investors. 4.7% of IDEAYA Biosciences shares are held by company insiders. Comparatively, 10.0% of CryoPort shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is IDYA or CYRX more profitable? CryoPort has a net margin of 41.57% compared to IDEAYA Biosciences' net margin of 0.00%. CryoPort's return on equity of -7.92% beat IDEAYA Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets IDEAYA BiosciencesN/A -14.24% -13.09% CryoPort 41.57%-7.92%-4.79% Do analysts prefer IDYA or CYRX? IDEAYA Biosciences presently has a consensus price target of $50.69, suggesting a potential upside of 74.18%. CryoPort has a consensus price target of $14.69, suggesting a potential upside of 4.91%. Given IDEAYA Biosciences' higher possible upside, equities research analysts clearly believe IDEAYA Biosciences is more favorable than CryoPort.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IDEAYA Biosciences 1 Sell rating(s) 1 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 2.82CryoPort 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89 Does the media favor IDYA or CYRX? In the previous week, CryoPort had 2 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 4 mentions for CryoPort and 2 mentions for IDEAYA Biosciences. CryoPort's average media sentiment score of 0.12 beat IDEAYA Biosciences' score of -0.17 indicating that CryoPort is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral CryoPort 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryCryoPort beats IDEAYA Biosciences on 11 of the 16 factors compared between the two stocks.How does CryoPort compare to Enliven Therapeutics?Enliven Therapeutics (NASDAQ:ELVN) and CryoPort (NASDAQ:CYRX) are both pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability. Do insiders & institutionals hold more shares of ELVN or CYRX? 95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 92.9% of CryoPort shares are held by institutional investors. 25.9% of Enliven Therapeutics shares are held by company insiders. Comparatively, 10.0% of CryoPort shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Do analysts prefer ELVN or CYRX? Enliven Therapeutics currently has a consensus price target of $58.40, suggesting a potential upside of 40.59%. CryoPort has a consensus price target of $14.69, suggesting a potential upside of 4.91%. Given Enliven Therapeutics' higher possible upside, research analysts plainly believe Enliven Therapeutics is more favorable than CryoPort.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enliven Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83CryoPort 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89 Which has higher earnings and valuation, ELVN or CYRX? CryoPort has higher revenue and earnings than Enliven Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnliven TherapeuticsN/AN/A-$103.69M-$1.67N/ACryoPort$176.18M4.00$78.30M$1.3510.37 Is ELVN or CYRX more profitable? CryoPort has a net margin of 41.57% compared to Enliven Therapeutics' net margin of 0.00%. CryoPort's return on equity of -7.92% beat Enliven Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Enliven TherapeuticsN/A -21.04% -20.41% CryoPort 41.57%-7.92%-4.79% Does the media refer more to ELVN or CYRX? In the previous week, CryoPort had 3 more articles in the media than Enliven Therapeutics. MarketBeat recorded 4 mentions for CryoPort and 1 mentions for Enliven Therapeutics. CryoPort's average media sentiment score of 0.12 beat Enliven Therapeutics' score of 0.00 indicating that CryoPort is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CryoPort 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, ELVN or CYRX? Enliven Therapeutics has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market. Comparatively, CryoPort has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market. SummaryCryoPort beats Enliven Therapeutics on 12 of the 16 factors compared between the two stocks.How does CryoPort compare to Disc Medicine?Disc Medicine (NASDAQ:IRON) and CryoPort (NASDAQ:CYRX) are both pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation. Do analysts prefer IRON or CYRX? Disc Medicine presently has a consensus price target of $105.30, indicating a potential upside of 57.59%. CryoPort has a consensus price target of $14.69, indicating a potential upside of 4.91%. Given Disc Medicine's higher probable upside, equities research analysts plainly believe Disc Medicine is more favorable than CryoPort.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Disc Medicine 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.75CryoPort 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89 Is IRON or CYRX more profitable? CryoPort has a net margin of 41.57% compared to Disc Medicine's net margin of 0.00%. CryoPort's return on equity of -7.92% beat Disc Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Disc MedicineN/A -36.94% -33.88% CryoPort 41.57%-7.92%-4.79% Does the media favor IRON or CYRX? In the previous week, Disc Medicine had 1 more articles in the media than CryoPort. MarketBeat recorded 5 mentions for Disc Medicine and 4 mentions for CryoPort. Disc Medicine's average media sentiment score of 0.60 beat CryoPort's score of 0.12 indicating that Disc Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CryoPort 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, IRON or CYRX? Disc Medicine has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market. Comparatively, CryoPort has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market. Which has preferable earnings & valuation, IRON or CYRX? CryoPort has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDisc MedicineN/AN/A-$212.18M-$6.62N/ACryoPort$176.18M4.00$78.30M$1.3510.37 Do institutionals & insiders have more ownership in IRON or CYRX? 83.7% of Disc Medicine shares are owned by institutional investors. Comparatively, 92.9% of CryoPort shares are owned by institutional investors. 3.8% of Disc Medicine shares are owned by insiders. Comparatively, 10.0% of CryoPort shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryCryoPort beats Disc Medicine on 11 of the 15 factors compared between the two stocks.How does CryoPort compare to Arcutis Biotherapeutics?CryoPort (NASDAQ:CYRX) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations. Do analysts recommend CYRX or ARQT? CryoPort presently has a consensus target price of $14.69, indicating a potential upside of 4.91%. Arcutis Biotherapeutics has a consensus target price of $34.00, indicating a potential upside of 62.99%. Given Arcutis Biotherapeutics' higher probable upside, analysts clearly believe Arcutis Biotherapeutics is more favorable than CryoPort.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CryoPort 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89Arcutis Biotherapeutics 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do insiders and institutionals believe in CYRX or ARQT? 92.9% of CryoPort shares are owned by institutional investors. 10.0% of CryoPort shares are owned by insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more volatility and risk, CYRX or ARQT? CryoPort has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the broader market. Is CYRX or ARQT more profitable? CryoPort has a net margin of 41.57% compared to Arcutis Biotherapeutics' net margin of -0.57%. Arcutis Biotherapeutics' return on equity of -1.41% beat CryoPort's return on equity.Company Net Margins Return on Equity Return on Assets CryoPort41.57% -7.92% -4.79% Arcutis Biotherapeutics -0.57%-1.41%-0.59% Does the media refer more to CYRX or ARQT? In the previous week, CryoPort had 4 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 4 mentions for CryoPort and 0 mentions for Arcutis Biotherapeutics. CryoPort's average media sentiment score of 0.12 beat Arcutis Biotherapeutics' score of 0.00 indicating that CryoPort is being referred to more favorably in the media. Company Overall Sentiment CryoPort Neutral Arcutis Biotherapeutics Neutral Which has better earnings and valuation, CYRX or ARQT? CryoPort has higher earnings, but lower revenue than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCryoPort$176.18M4.00$78.30M$1.3510.37Arcutis Biotherapeutics$376.07M6.94-$16.14M-$0.03N/A SummaryCryoPort beats Arcutis Biotherapeutics on 11 of the 16 factors compared between the two stocks. Get CryoPort News Delivered to You Automatically Sign up to receive the latest news and ratings for CYRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYRX vs. The Competition ExportMetricCryoPortTRANS IndustryTransportation SectorNASDAQ ExchangeMarket Cap$705.63M$6.86B$8.53B$12.34BDividend YieldN/A2.67%956.00%5.28%P/E Ratio10.3719.4423.1525.65Price / Sales4.001.977.6586.28Price / CashN/A9.348.3456.67Price / Book1.572.432.287.14Net Income$78.30M$257.31M$539.59M$335.98M7 Day Performance5.18%1.68%1.99%3.56%1 Month Performance32.20%-8.49%1.32%2.54%1 Year Performance131.79%1.36%37.57%35.05% CryoPort Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYRXCryoPort3.1558 of 5 stars$14.00flat$14.69+4.9%+131.8%$705.63M$176.18M10.371,186GPCRStructure Therapeutics3.0279 of 5 stars$36.87+2.8%$109.25+196.3%+59.6%$2.54BN/AN/A136IDYAIDEAYA Biosciences3.239 of 5 stars$29.65+4.7%$50.69+71.0%+54.6%$2.49B$218.71MN/A80Positive NewsAnalyst ForecastGap UpELVNEnliven Therapeutics2.8496 of 5 stars$41.86+4.2%$58.40+39.5%+153.3%$2.45BN/AN/A50Gap UpIRONDisc Medicine2.3566 of 5 stars$67.03+4.6%$105.30+57.1%+41.1%$2.44BN/AN/A30 Related Companies and Tools Related Companies Structure Therapeutics Competitors IDEAYA Biosciences Competitors Enliven Therapeutics Competitors Disc Medicine Competitors Arcutis Biotherapeutics Competitors Kailera Therapeutics Competitors Vera Therapeutics Competitors Relay Therapeutics Competitors Nanobiotix Competitors Immunome Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYRX) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CryoPort, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CryoPort With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
